Published in Hepatitis Weekly, April 24th, 2000
The researchers, led by G. Fattovich, conducted a retrospective cohort study of 200 patients in Europe who had compensated cirrhosis type B. These patients were followed for a median period of 6.6 years, according to the study report.
"Kaplan-Meier five-year probability of hepatocellular carcinoma (HCC) was 6, 10, and 9% in anti-HDV positive/HbeAg negative, anti-HDV negative/HbeAg negative, and anti-HDV negative /HbeAg positive cirrhotics, respectively,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.